Loading…
Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
Correction to: Leukemia (2016) 30, 1701-1707; doi:10.1038/leu.2016.148 Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high...
Saved in:
| Published in: | Leukemia 2017-03, Vol.31 (3), p.775-775 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3653-dba238a557c3583495455c878fae139819593818ded85611109863ece309005e3 |
|---|---|
| cites | |
| container_end_page | 775 |
| container_issue | 3 |
| container_start_page | 775 |
| container_title | Leukemia |
| container_volume | 31 |
| creator | Harrison, C N Vannucchi, A M Kiladjian, J-J Al-Ali, H K Gisslinger, H Knoops, L Cervantes, F |
| description | Correction to: Leukemia (2016) 30, 1701-1707; doi:10.1038/leu.2016.148 Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original. |
| doi_str_mv | 10.1038/leu.2016.323 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7609269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A689287022</galeid><sourcerecordid>A689287022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3653-dba238a557c3583495455c878fae139819593818ded85611109863ece309005e3</originalsourceid><addsrcrecordid>eNptkt9r2zAQx8XYWLNub_sDBIM91Zl-WLK8h0EJbRfICIzuWcj2KVaRpUyys-W_n0NLt8C4h4O7z325O74IvadkSQlXnzxMS0aoXHLGX6AFLStZCCHoS7QgSlWFrFl5gd7k_EDIqSlfowumWKk45Qv06yYlM07DZ7yJYVeMkAZsXehc2GVsUxzwavvtdvv9vlivr7DB-95kwBznceqOOFqcpt_Ru9EF1-BDxg3kEZuDcd40HvDYQzL7I7Yx4eEIPlrXpJhdfoteWeMzvHvKl-jH7c396mux2d6tV9ebouVS8KJrDOPKCFG1XChe1qIUolWVsgYorxWtRc0VVR10SkhKKamV5NACJzUhAvgl-vKou5-aAboWwpiM1_vkBpOOOhqnzzvB9XoXD7qSpGayngU-PAmk-HOar9MPcUph3lkzSYXgJSfsL7UzHrQLNs5i7eByq6-lqpmqCDtRy_9Qc3QwuDYGsG6unw18_GegB-PHPkc_jS6GfA5ePYLt_N2cwD5fSIk-2UTPNtEnm-jZJvwP29-sAw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2615534302</pqid></control><display><type>article</type><title>Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis</title><source>Springer Link</source><creator>Harrison, C N ; Vannucchi, A M ; Kiladjian, J-J ; Al-Ali, H K ; Gisslinger, H ; Knoops, L ; Cervantes, F</creator><creatorcontrib>Harrison, C N ; Vannucchi, A M ; Kiladjian, J-J ; Al-Ali, H K ; Gisslinger, H ; Knoops, L ; Cervantes, F</creatorcontrib><description>Correction to: Leukemia (2016) 30, 1701-1707; doi:10.1038/leu.2016.148 Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/leu.2016.323</identifier><identifier>PMID: 28248313</identifier><language>eng</language><publisher>London: Nature Publishing Group</publisher><subject>Erratum</subject><ispartof>Leukemia, 2017-03, Vol.31 (3), p.775-775</ispartof><rights>COPYRIGHT 2017 Nature Publishing Group</rights><rights>Macmillan Publishers Limited, part of Springer Nature. 2017.</rights><rights>Macmillan Publishers Limited, part of Springer Nature. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3653-dba238a557c3583495455c878fae139819593818ded85611109863ece309005e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids></links><search><creatorcontrib>Harrison, C N</creatorcontrib><creatorcontrib>Vannucchi, A M</creatorcontrib><creatorcontrib>Kiladjian, J-J</creatorcontrib><creatorcontrib>Al-Ali, H K</creatorcontrib><creatorcontrib>Gisslinger, H</creatorcontrib><creatorcontrib>Knoops, L</creatorcontrib><creatorcontrib>Cervantes, F</creatorcontrib><title>Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis</title><title>Leukemia</title><description>Correction to: Leukemia (2016) 30, 1701-1707; doi:10.1038/leu.2016.148 Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.</description><subject>Erratum</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNptkt9r2zAQx8XYWLNub_sDBIM91Zl-WLK8h0EJbRfICIzuWcj2KVaRpUyys-W_n0NLt8C4h4O7z325O74IvadkSQlXnzxMS0aoXHLGX6AFLStZCCHoS7QgSlWFrFl5gd7k_EDIqSlfowumWKk45Qv06yYlM07DZ7yJYVeMkAZsXehc2GVsUxzwavvtdvv9vlivr7DB-95kwBznceqOOFqcpt_Ru9EF1-BDxg3kEZuDcd40HvDYQzL7I7Yx4eEIPlrXpJhdfoteWeMzvHvKl-jH7c396mux2d6tV9ebouVS8KJrDOPKCFG1XChe1qIUolWVsgYorxWtRc0VVR10SkhKKamV5NACJzUhAvgl-vKou5-aAboWwpiM1_vkBpOOOhqnzzvB9XoXD7qSpGayngU-PAmk-HOar9MPcUph3lkzSYXgJSfsL7UzHrQLNs5i7eByq6-lqpmqCDtRy_9Qc3QwuDYGsG6unw18_GegB-PHPkc_jS6GfA5ePYLt_N2cwD5fSIk-2UTPNtEnm-jZJvwP29-sAw</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Harrison, C N</creator><creator>Vannucchi, A M</creator><creator>Kiladjian, J-J</creator><creator>Al-Ali, H K</creator><creator>Gisslinger, H</creator><creator>Knoops, L</creator><creator>Cervantes, F</creator><general>Nature Publishing Group</general><general>Nature Publishing Group UK</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20170301</creationdate><title>Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis</title><author>Harrison, C N ; Vannucchi, A M ; Kiladjian, J-J ; Al-Ali, H K ; Gisslinger, H ; Knoops, L ; Cervantes, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3653-dba238a557c3583495455c878fae139819593818ded85611109863ece309005e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Erratum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harrison, C N</creatorcontrib><creatorcontrib>Vannucchi, A M</creatorcontrib><creatorcontrib>Kiladjian, J-J</creatorcontrib><creatorcontrib>Al-Ali, H K</creatorcontrib><creatorcontrib>Gisslinger, H</creatorcontrib><creatorcontrib>Knoops, L</creatorcontrib><creatorcontrib>Cervantes, F</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harrison, C N</au><au>Vannucchi, A M</au><au>Kiladjian, J-J</au><au>Al-Ali, H K</au><au>Gisslinger, H</au><au>Knoops, L</au><au>Cervantes, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis</atitle><jtitle>Leukemia</jtitle><date>2017-03-01</date><risdate>2017</risdate><volume>31</volume><issue>3</issue><spage>775</spage><epage>775</epage><pages>775-775</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><notes>erratum</notes><abstract>Correction to: Leukemia (2016) 30, 1701-1707; doi:10.1038/leu.2016.148 Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.</abstract><cop>London</cop><pub>Nature Publishing Group</pub><pmid>28248313</pmid><doi>10.1038/leu.2016.323</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2017-03, Vol.31 (3), p.775-775 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7609269 |
| source | Springer Link |
| subjects | Erratum |
| title | Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T09%3A35%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erratum:%20Long-term%20findings%20from%20COMFORT-II,%20a%20phase%203%20study%20of%20ruxolitinib%20vs%20best%20available%20therapy%20for%20myelofibrosis&rft.jtitle=Leukemia&rft.au=Harrison,%20C%20N&rft.date=2017-03-01&rft.volume=31&rft.issue=3&rft.spage=775&rft.epage=775&rft.pages=775-775&rft.issn=0887-6924&rft.eissn=1476-5551&rft_id=info:doi/10.1038/leu.2016.323&rft_dat=%3Cgale_pubme%3EA689287022%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3653-dba238a557c3583495455c878fae139819593818ded85611109863ece309005e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2615534302&rft_id=info:pmid/28248313&rft_galeid=A689287022&rfr_iscdi=true |